) has been revised to $8.16 / share. This is a decrease of 27.27% from the prior estimate of $11.22 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...
GT Biopharma targets a portion of the estimated $362 billion global solid tumor marketPreliminary, unaudited cash balance of approximately $7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results